2B70:XETRA:XETRA-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (EUR)

ETF | Others |

Last Closing

USD 5.644

Change

+0.10 (+1.73)%

Market Cap

USD 0.52B

Volume

0.24M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.22 (+0.43%)

USD 450.46B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

+0.07 (+0.44%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.10 (+0.38%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.11 (+0.40%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

+0.21 (+0.86%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

-1.10 (-0.71%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

+1.14 (+0.83%)

USD 104.09B
JARI:XETRA Amundi Index Solutions - Amund..

+0.21 (+0.47%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.24 (+0.48%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+4.85 (+0.98%)

USD 80.38B

ETFs Containing 2B70:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.05% 18% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.05% 18% F 23% F
Trailing 12 Months  
Capital Gain 1.58% 24% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.58% 24% F 31% F
Trailing 5 Years  
Capital Gain 32.41% 56% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 32.41% 55% F 56% F
Average Annual (5 Year Horizon)  
Capital Gain 6.75% 64% D 62% D
Dividend Return 6.75% 63% D 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.67% 41% F 52% F
Risk Adjusted Return 45.98% 59% D- 62% D
Market Capitalization 0.52B 69% C- 61% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.